

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number  
**WO 03/072121 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 35/78**,  
A61P 3/04, 3/10

F.F.I., Inc., 1-11, Sanwamachi 1-chome, Toyonaka-shi, Osaka 561-8588 (JP).

(21) International Application Number: PCT/JP02/06826

(74) Agent: **NOGAWA, Shintaro**; MINAMIMORIMACHI PARK BLDG., 1-3, Nishitenma 5-chome, Kita-ku, Osaka-shi, Osaka 530-0047 (JP).

(22) International Filing Date: 4 July 2002 (04.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2002-54286 28 February 2002 (28.02.2002) JP

(71) Applicant (for all designated States except US): **SAN-EI GEN F.F.I., INC.** [JP/JP]; 1-11, Sanwamachi 1-chome, Toyonaka-shi, Osaka 561-8588 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TSUDA, Takanori** [JP/JP]; 1015-302, Otokikiyama, Tenpaku-ku, Nagoya-shi, Aichi 468-0063 (JP). **HORIO, Fumihiko** [JP/JP]; 2-24-1-303, Yatomigaoka, Mizuho-ku, Mizuho-ku, Nagoya-shi, Aichi 467-0048 (JP). **OSAWA, Toshihiko** [JP/JP]; 2615-409, Tokugawacho, Higashi-ku, Higashi-ku, Nagoya-shi, Aichi 461-0023 (JP). **UCHIDA, Koji** [JP/JP]; San-Ei Gen F.F.I., Inc., 1-11, Sanwamachi 1-chome, Toyonaka-shi, Osaka 561-8588 (JP). **AOKI, Hiromitsu** [JP/JP]; San-Ei Gen F.F.I., Inc., 1-11, Sanwamachi 1-chome, Toyonaka-shi, Osaka 561-8588 (JP). **KODA, Takatoshi** [JP/JP]; San-Ei Gen

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ANTIOBESITIC AND/OR ANTIDIABETIC AGENT CONTAINING CYANIDIN 3-GLUCOSIDE AS ACTIVE INGREDIENT**

(57) Abstract: The invention provides an antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as an active ingredient. Thereby the increase of adipose cells can be suppressed and the blood glucose level can be reduced safely and effectively.



**WO 03/072121 A1**

## DESCRIPTION

Antiobestic and/or Antidiabetic Agent Containing  
Cyanidin 3-Glucoside as Active Ingredient

## 5 Technical Field

The present invention relates to an antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as an active ingredient and a health food to which cyanidin 3-glucoside or a water-soluble extract from a plant containing cyanidin  
10 3-glucoside is added.

## Background Art

Recently, as western diet becomes more prevailing, obesity keeps on increasing. The obesity is condition of  
15 adipose tissue increasing beyond its normal proportion in a body because of excessive intake of sugars (carbohydrates) and fats.

Normally, the sugars and fats, after being decomposed by digestive enzymes, are used as an energy source or the like. However,  
20 if taken excessively, an excess of sugars is changed into fatty acids via acetyl CoA and stored in tissue together with fats, resulting in obesity.

Adipose cells storing fats secrete free fatty acids and a tumor necrosis factor (TNF) and inhibit the action of insulin which regulates metabolism of sugar including blood glucose, fats and amino acids.  
25 Therefore, if adipose cells increase owing to obesity, insulin does not

act well and blood glucose increases to cause diabetes. It has been pointed out that the illness, if it hangs on for a long time, leads to peripheral vessel disorder and arterial sclerosis.

Anthocyanin pigments having a wide distribution in the plant  
5 kingdom are used as colorants, but are also known to have an decreasing effect on cholesterol in blood, for example, as bioactivity (*Agric. Biol. Chem.*, 54(1), 171-175, 1990).

Cholesterol is a constituent of biological membrane and serum lipoprotein and is synthesized *in vivo*. Normally, if cholesterol  
10 is externally taken, the amount of cholesterol synthesized *in vivo* is suppressed. However, if a large amount of cholesterol is taken, a cholesterol balance in the body is lost, which results in hypercholesterolemia. Excessive cholesterol causes arterial sclerosis. However, correlation between obesity and cholesterol is not known at  
15 present, and the control of cholesterol is not anticipated to lead to the control of weight.

Japanese Unexamined Patent Application Publication No. 2000-178295 described that cyanidin glucosides have an antitumor effect and that the intake of food containing cyanidin glucosides as  
20 active ingredients is preferable for prevention of or amelioration from diseases such as hyperlipidemia, arterial sclerosis, diabetes, fatty liver, myocardial infarction and the like. However, this reference presents pharmacological data supporting only the antitumor effect of the cyanidin glucosides, but does not present any pharmacological data  
25 about the antiobestic or antidiabetic effect thereof. It cannot be

considered from medical findings that the antitumor effect results in amelioration from obesity or from the above-mentioned diseases.

#### Disclosure of Invention

5           Under these circumstances, the present inventors have found that cyanidin 3-glucoside suppresses increase of adipose cells and reduces the blood glucose level, to accomplish the present invention.

          Accordingly, the present invention provides an  
10   antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as an active ingredient and a health food to which cyanidin 3-glucoside or a water-soluble extract from a plant containing cyanidin 3-glucoside is added.

#### 15   Brief Description of Drawings

          Fig. 1 is a photograph of epididymal adipose tissue of group C ( $\times 200$ ) in Example 2;

          Fig. 2 is a photograph of epididymal adipose tissue of group A ( $\times 200$ ) in Example 2;

20           Fig. 3 is a photograph of epididymal adipose tissue of group H ( $\times 200$ ) in Example 2; and

          Fig. 4 is a photograph of epididymal adipose tissue of group HA ( $\times 200$ ) in Example 2.

#### 25   Best Mode for Carrying Out the Invention

In the present invention, cyanidin 3-glucoside can be obtained from a plant material, but may be obtained by a semisynthetic or whole synthetic method using a technique known in the field of art.

5           In the case where cyanidin 3-glucoside is to be obtained from a plant, may be used one material or two or more materials selected from the group consisting of purple corn, red cabbage, berries such as strawberry, boysenberry, raspberry, cranberry, blackberry and blueberry, grains such as wild rice, red rice, black rice and the like,  
10    tamarind, peanut, grape and hibiscus. Any portion of these plants, such as stems, leaves, roots, petals, fruits and seeds, or tissue culture cells thereof may be used. For example, kernels or cobs of purple corn, fruits of berries, pericarps and juice of grapes, and petals of hibiscus are preferably used.

15           The method of obtaining cyanidin 3-glucoside from a plant is not particularly limited. For example, since cyanidin compounds are stable under an acidic condition, the plant may be macerated in a warm or cool liquid under an acidic condition adjusted within the range of about pH 1 to pH 4 with  
20    use of an inorganic acid such as sulfuric acid or an organic acid such as citric acid, for 4 to 12 hours, for example, overnight to extract a pigment and form a water-soluble extract therefrom. The extract may be used as it is or may be filtered and used as filtrate.

25           For the extraction, the plant may be used directly or

cut or crushed into an appropriate size. Alternatively, dried plants in these various shapes may be used.

The thus obtained water-soluble extract is thought to contain anthocyanin pigments such as cyanidin 3-glucoside as  
5 well as carbohydrates, salt and the like.

For this reason, the water-soluble extract may be refined to isolate cyanidin 3-glucoside by combining one or more treatments such as those using ion exchange resins or non-ionic adsorptive resins and filtration or by repeating a  
10 single treatment under the same or different conditions.

In the case where the extract is refined with a non-ionic adsorptive resin, may be used, for example, Duolite S-861, Duolite S-862, Duolite S-863 or Duolite S-866 of styrene series (trade names manufactured by Diamond  
15 Shamrock U.S.A.); Sepabeads SP70, Sepabeads SP700, Sepabeads SP825 or Sepabeads SP207 of aromatic series (trade names manufactured by Mitsubishi Chemical Corporation); Diaion HP10, Diaion HP20, Diaion HP21, Diaion HP40 or  
Diaion HP50 (trade names manufactured by Mitsubishi  
20 Chemical Corporation); Amberlite XAD-4, Amberlite XAD-7 or Amberlite XAD-2000 (trade names manufactured by Organo Corporation).

In the case where an ion exchange resin is used, may be used as a cation exchange resin, for example, Diaion SK 1B,  
25 Diaion SK 102, Diaion SK 116, Diaion PK 208, Diaion WK 10

or Diaion WK 20 (trade names manufactured by Mitsubishi Chemical Corporation), and may be used as an anion exchange resin, for example, Diaion SA 10A, Diaion SA 12A, Diaion SA 20A, Diaion PA 306, Diaion WA 10 or Diaion WA 20 (trade  
5 names manufactured by Mitsubishi Chemical Corporation).

The filtration may be ultrafiltration or reverse osmosis using various functional polymer membranes.

The inventors of the present invention have realized that cyanidin 3-glucoside obtained by the above-mentioned  
10 method suppresses increase of adipose cells and/or reduces the blood glucose level.

Accordingly, the present invention provides an antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside or a water-soluble plant extract containing  
15 cyanidin 3-glucoside as an active ingredient.

The agent is manufactured by a conventional method using a solid or liquid excipient known in the art. The solid excipients include, for example, lactose, sucrose, glucose, corn starch, gelatin, starch, dextrin, calcium phosphate, calcium  
20 carbonate, synthetic and natural aluminum silicate, magnesium oxide, dried aluminum hydroxide, magnesium stearate, sodium bicarbonate, dry yeast and the like. The liquid excipients include, for example, water, glycerin, propylene glycol, simple syrup, ethanol, ethylene glycol,  
25 polyethylene glycol, sorbitol and the like.

The above-described agent may contain conventional additives such as stabilizers including citric acid, phosphoric acid, malic acid and salts thereof; sweeteners of high potency including sucralose, acesulfame K and the like, and sweeteners  
5 such as sucrose, fructose and the like; preservatives including alcohols, glycerin and the like; demulcentias, diluents, buffers, flavoring agents and coloring agents, if desired. The agent may be manufactured into forms for internal use such as dispersion, tablet, emulsion, capsule, granule, chewable tablet,  
10 solution, syrup and the like by a conventional method or other suitable method.

The health food as used in the present invention signifies a food positively intended for health care, health maintenance and health enhancement compared with common  
15 food. The food added with cyanidin 3-glucoside or the water soluble plant extract containing cyanidin 3-glucoside according to the present invention can be the health food expected to exhibit effects of preventing, treating or ameliorating obesity and/or diabetes.

20 For example, the health food used for the above-mentioned purposes can be obtained by mixing or spraying cyanidin 3-glycoside or the water soluble plant extract containing cyanidin 3-glucoside of the invention with or into an intermediate product under processing or a final  
25 product, for example, solid, liquid or semisolid products usable



itself as food such as starch, wheat flour, sugar and syrup; for example, bread, noodles, sweets including candies and cookies, other solid products; flavor enhancers such as dressings and sauces ; liquid products such as beverage, nutritional drink  
5 and soup ; semisolid products such as jerry.

As for the dose of cyanidin 3-glucoside of the invention, it is preferably used to an adult of 60 kg in an amount of 10 to 100 mg a day. However, the dose may vary depending on various factors such as health conditions of a  
10 person who will take cyanidin 3-glucoside, an administration method and a combination with other agents.

Cyanidin 3-glucoside of the present invention can be used safely and effectively as a substance for preventing, treating or ameliorating obesity and/or diabetes and, in  
15 additional to that, it has the feature of being able to be manufactured economically, because cyanidin 3-glucoside is contained in a lot of species of natural plants and has been used as a food additive.

## 20 Examples

Hereinafter, the present invention will be detailed with reference to examples, but the invention is not limited thereto.

### **Example 1:**

To a mixture solution of 100 L of water and 450 g  
25 sulfuric acid (pH 2.3), 10 kg of dried purple corn (cobs and

kernels) were added and allowed to stand overnight at room temperature to extract a pigment. After extraction, solid-liquid separation was performed using a metal gauze of 60 mesh. To the resulting liquid, was added a 2 % filter aid  
5 (Radiolite #700 manufactured by Showa Kagaku Kogyo Co., Ltd.) and filtration was carried out to obtain about 100 L of a crude extract of purple corn.

The crude extract was subjected to adsorption using 10 L of adsorptive resin (styrene vinyl benzene copolymer;  
10 Diaion HP20 manufactured by Mitsubishi Chemical Corporation) under the conditions of  $SV = 1$  and a temperature of  $20^{\circ}\text{C}$ , and the resin was washed with 30 L ( $SV = 1$ ) of water. Further, 15 L of 30 v/v% of ethanol aqueous solution containing 0.2 wt/v% of citric acid were passed through the  
15 resin ( $SV = 1$ , temperature :  $20^{\circ}\text{C}$ ), to collect eluate. The obtained eluate was concentrated under reduced pressure below  $40^{\circ}\text{C}$ , to obtain a purple corn extract.

The purple corn extract was then passed through 10 L of Sepabeads SP207, adsorptive resin, (manufactured by  
20 Mitsubishi Chemical Corporation) under the conditions of  $SV = 1$  and a temperature of  $20^{\circ}\text{C}$ , and the resin was washed with 30 L ( $SV = 1$ ) of water and then with 10 L of 15 v/v% of ethanol aqueous solution containing 0.2 wt/v% of citric acid ( $SV = 1$ ). Further, 20 L of 25 v/v% of ethanol aqueous solution  
25 containing 0.2 wt/v% of citric acid were passed through the

resin (SV = 1, temperature : 20 °C), to collect eluate.

The eluate was concentrated under reduced pressure below 40 °C and then was spray-dried to obtain 70 g of a powdered purple corn extract of dark red color.

5 This powder contained 18.5 % of cyanidin 3-glucoside.

**Example 2 :**

The action of cyanidin 3-glucoside was evaluated by adding the extract obtained in Example 1 to a normal diet (control diet) and to a diet containing fats in a higher  
10 proportion (high fat diet).

Four-week old C57BL/6J mice were allocated into four groups (6 to 8 mice per group), which were given the control diet (group C), the control diet + the extract obtained in Example 1 (group A), the high fat diet (group H) and the high  
15 fat diet + the extract obtained in Example 1 (group HA), respectively. The diets were taken freely for 12 weeks.

The control diet, 1 kg, was composed of 204 g of casein, 35 g of mixed minerals, 10 g of mixed vitamins, 2 g of choline chloride, 50 g of corn oil, 40 g of powered cellulose and  
20 659 g of sucrose. The high fat diet, 1 kg, was composed of 204 g of casein, 35 g of mixed minerals, 10 g of mixed vitamins, 2 g of choline chloride, 50 g of corn oil, 40 g of powered cellulose, 300 g of lard, and 359 g of sucrose. In groups A and HA, the extract of Example 1 was added so that the  
25 content of cyanidin 3-glucoside was 0.2 % in the control diet

and the high fat diet, and sucrose given as part of the diets was deducted by the amount of cyanidin 3-glucoside added.

(1) Measurement of Weight and intake amount of diet

The amount of diet taken by each mouse a day was weighed 2, 4, 6, 10 and 12 weeks after the start of dieting the animals (Table 1).

Table 1

	2 weeks	4 weeks	6 weeks	10 weeks	12 weeks
Group C	3.2	5.0	7.4	5.4	3.2
Group A	3.1	4.9	7.4	5.2	3.7
Group H	2.1	3.0	3.5	2.5	2.9
Group HA	2.3	3.9	3.6	2.2	2.6

\* Unit is diet intake amount (g)/day/mouse

10

As shown in Table 1, since the high fat diet was high in calories, the intake amount of groups H and HA was smaller than that of groups C and A. However, no significant difference was observed in the intake amount between group C and group A or between group H and group HA.

After 12 weeks, the mice were weighed and BMI (Body Mass Index = weight (kg)  $\times$  body length (m)<sup>2</sup>) was calculated, and subcutaneous fat and epididymal peripheral fat were weighed (Table 2, values represent average  $\pm$  standard error). Also epididymal adipose tissue was photographed (Figs. 1 to 4).

Table 2

	Weight (g)	BMI	Subcutaneous fat (%)	Epididymal peripheral fat (%)
Group C	30.5 ± 0.6	9.5 ± 0.4	1.7 ± 0.2	2.7 ± 0.2
Group A	29.7 ± 0.3	8.9 ± 0.2	1.5 ± 0.3	2.1 ± 0.2
Group H	38.9 ± 1.3	14.3 ± 0.9	3.2 ± 0.3	5.6 ± 0.4
Group HA	29.8 ± 0.7	8.7 ± 0.3	1.7 ± 0.2	3.3 ± 0.4

As shown in Table 2, group H showed significant increase in weight, BMI and adipose tissue amount as compared with group C, but group HA given the purple corn extract of Example 1 showed significant suppression in weight, BMI and adipose tissue amount. No significant difference was recognized among group C, group A and group HA.

As shown in Figs. 1 to 4, the size of epididymal adipose cells increased in group H. However, in group HA given the purple corn extract of Example 1, the size of adipose cells remained almost the same as that in group C, although group HA took the high fat diet.

2) Measurement of blood glucose level, serum insulin concentration and serum leptin concentration

Blood was collected from mice raised for 12 weeks. Glucose concentration, insulin concentration and leptin concentration in serum were measured with Glucose B - Test Kit (manufactured by Wako Junyaku Kogyo), Lbis® Insulin Kit (for mice - T, manufactured by Shibayagi Company) and Leptin Mouse Kit (manufactured by Morinaga Company), respectively (Table 3).

Table 3

	Serum glucose (mg/100mL)	Serum insulin (ng/mL)	Serum leptin (ng/mL)
Group C	232.2 $\pm$ 6.2	1.8 $\pm$ 0.05	15.3 $\pm$ 2.4
Group A	219.8 $\pm$ 13.9	1.8 $\pm$ 0.09	15.1 $\pm$ 2.2
Group H	362.3 $\pm$ 10.4	3.0 $\pm$ 0.20	118.1 $\pm$ 10.3
Group HA	254.3 $\pm$ 13.7	1.8 $\pm$ 0.05	20.2 $\pm$ 2.2

The concentration of serum glucose, serum insulin and serum leptin, which is a hormone having antiobestic action, increased significantly in group H as compared with group C. Group H was considered to have hyperinsulinemia and hyperleptinemia due to the intake of high fat diet.

Those values were remarkably decreased by dieting the purple corn extract of Example 1 (group HA). That is, the intake of the purple corn extract suppressed hyperglycemia and avoided hyperinsulinemia and hyperleptinemia. No significant difference was recognized in these concentrations among groups C, group A and group HA.

### (3) Measurement of mRNAs of fatty acid synthetases and of leptin

The increase of adipose cells involves increase of fatty acid synthetases and leptin at a molecular level. Therefore, the amount of expressed mRNAs of hepatic fatty acid synthetases and leptin was measured by RT-PCR.

Livers were taken out of mice raised for 12 weeks and immediately frozen in liquid nitrogen. Subsequently, the total RNAs were extracted from the livers using DNA and RNA extraction reagents

and Isogen (manufactured by Nippon Gene) according to the conventional method and were subjected to the RT-PCR to obtain the results shown in Table 4.

5 Table 4

	Fatty acid synthetases / Actin Expressed amount	Leptin / Actin Expressed amount
Group C	0.84 ± 0.06	0.45 ± 0.04
Group A	0.56 ± 0.02	0.39 ± 0.04
Group H	0.28 ± 0.04	0.80 ± 0.07
Group HA	0.16 ± 0.01	0.46 ± 0.07

The amount of expressed mRNAs of the fatty acid synthetases was significantly smaller in group A than in group C, and was significantly smaller in group HA than in H. It was confirmed that the synthesis of fatty acids at the molecular level was affected by the purple corn extract of Example 1. The amount of expressed mRNAs of leptin was significantly larger in group H than in groups C, A and HA. Correlation between the amount of expressed mRNAs of leptin and the serum leptin concentration was confirmed.

15 Thus, it was shown that the purple corn extract containing cyanidin 3-glucoside did not suppress the increase of weight, fat and blood glucose level with regard to the ordinary diet but significantly suppresses it with regard to the high fat diet.

### Example 3 :

20 NOD mice which were an I type human diabetes model (purchased from Clea Japan Inc.) were administered with the extract

obtained in Example 1 and the incidence of diabetes was examined.

Six-week-old female NOD mice were allocated into two groups, 16 mice per group, which were given a control diet (pellet CA-1 manufactured by Clea Japan Inc., group NC) and a control diet plus the extract obtained in Example 1 (group NA) for 24 weeks. The diets were taken freely. The incidence of diabetes was observed using dip stick sheets for urinary sugar (Table 5). In group NA, the extract of Example 1 was added so that the content of cyanidin 3-glucoside in the control diet was 0.2 %, and sucrose was deduced from the control diet by the amount of cyanidin 3-glucoside added.



Table 5

Incidence of diabetes(%)

Experiment diet intake weeks	0-7W	8W	9W	10W	11W	13W	14W	15W	16W	17W	18W	19W	20W	21W	22W	23W	24W
Group NC	0	6.2	12.5	12.5	12.5	12.5	18.7	18.7	18.7	18.7	31.1	31.1	43.5	43.5	50	50	50
Group NA	0	0	0	0	0	0	0	0	6.2	6.2	6.2	6.2	6.2	6.2	12.5	12.5	18.7

In group NA given the diet containing the purple corn extract of Example 1, the incidence of diabetes is significantly smaller as compared with group NC.

It was shown that the purple corn extract containing  
 5 cyanidin 3-glucoside suppressed not only the incidence of diabetes when the high fat diet was given but also the incidence of type I diabetes.

**Example 4 :**

Using the purple corn extract obtained in Example 1,  
 10 materials were blended according to the following formula. The resulting mixture was filtrated, and was put in a 250-mL bottle and was sterilized at 60°C for 20 minutes to prepare a carbonated beverage containing 20 % of grape juice. The beverage, 250 mL, contained about 50 mg of cyanidin  
 15 3-glucoside.

	Unit (kg)	
	Sucralose	0.0136
	x5 concentrated transparent grape juice	4.0
	Citric acid (crystalline)	0.25
20	Purple corn extract	0.1
	Grape flavor	0.10
	Fruit flavor	0.10
	Water	proper amount
	Total	45.0 kg

25 The above syrup was mixed with 55.0 kg carbonated water to

make the total amount 100.0 kg.

**Example 5 :**

Using the purple corn extract obtained in Example 1,  
5 materials were blended according to the following formula, and  
was prepared into tablets by a tablet machine. The tablets,  
10 g, contained about 50 mg of cyanidin 3-glucoside.

Unit (kg)		
	Fine powdered glucose	87.8
10	10 w/w% corn starch	7.0
	Citric acid (crystalline)	1.5
	Grape flavor	1.0
	Purple corn extract	2.7
<hr/>		
	Total	100.0 kg

15

According to the present invention, the cyanidin compound  
naturally contained in a lot of species of plants can be utilized as  
antiobestic and/or antidiabetic agents for suppressing the increase of  
adipose cells and reducing blood glucose level safely and effectively.

20

## CLAIMS

1. An antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as an active ingredient.
2. An agent as recited in claim 1, wherein cyanidin 3-glucoside  
5 is used as a water-soluble extract from a plant.
3. An agent as recited in claim 2, wherein the plant is purple corn.
4. An agent as recited in any one of claims 1 to 3, which suppresses increase of adipose cells and/or reduces blood glucose  
10 level.
5. An agent as recited in any one of claims 1 to 4, which is used by being added to food for use.
6. A health food containing cyanidin 3-glucoside or a water-soluble plant extract containing cyanidin 3-glucoside, which is  
15 used for preventing, treating or ameliorating obesity and/or diabetes.

Fig.1




Fig.2




Fig.3





Fig.4



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 02/06826

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K35/78 A61P3/04 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, MEDLINE, CHEM ABS Data, EMBASE, PHARMAPROJECTS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 49281 A (PROTEO TECH INC) 12 July 2001 (2001-07-12) *cf. page 8 bridging with page 9, lines 1-23, page 12, lines 18-25*	1-6
X	PATENT ABSTRACTS OF JAPAN vol. 1999, no. 13, 30 November 1999 (1999-11-30) & JP 11 218572 A (FUJI ELECTRIC CO LTD), 10 August 1999 (1999-08-10) *cf. abstract*	1-6
X	US 4 229 439 A (MAJOIE BERNARD) 21 October 1980 (1980-10-21) *cf. col. 1, lines 1-31, col. 2, lines 12-36*	1-6

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

25 November 2002

Date of mailing of the international search report

03/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Stoltner, A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 02/06826

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOHANSEN O-P ET AL: "CYANIDIN 3-Ä6-(P-COUMAROYL)-2-(XYLOSYL)-GLUCOSIDEÜ- 5-GLUCOSIDE AND OTHER ANTHOCYANINS FROM FRUITS OF SAMBUCUS CANADENSIS" PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 30, no. 12, 1991, pages 4137-4141, XP001120128 ISSN: 0031-9422 *cf. abstract, page 4137, left-sided col., "Introduction" and 1st para. of "Results and Discussion"* -----	1-6
X	US 2001/016573 A1 (MURALEEDHARAN G. NAIR, ET AL.) 23 August 2001 (2001-08-23) *cf. abstract, page 1, feature '0006!, page 2, feature '0023! and fig. 1, page 3, feature '0037!*	1-6
A	EP 0 815 857 A (SUNTORY LTD) 7 January 1998 (1998-01-07) *cf. abstract, page 4, lines 45-50* -----	1-6

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 02/06826

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0149281	A	12-07-2001	US 2001047032 A1 AU 2612101 A EP 1244435 A2 WO 0149281 A2	29-11-2001 16-07-2001 02-10-2002 12-07-2001
JP 11218572	A	10-08-1999	NONE	
US 4229439	A	21-10-1980	NONE	
US 2001016573	A1	23-08-2001	AU 2946101 A WO 0154516 A1	07-08-2001 02-08-2001
EP 0815857	A	07-01-1998	EP 0815857 A1 US 6294190 B1 WO 9723210 A1 JP 9291039 A	07-01-1998 25-09-2001 03-07-1997 11-11-1997